Avirmax, Inc.

📍 Hayward, United States🗓 Founded 2019👥 13 employees💰 Last funded Feb 2020
Biotechnology🌐 avirmax.com
Website LinkedIn
Avirmax, Inc. based in San Francisco Bay Area, is dedicated to innovate, develop and manufacture adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and BAC-to-AAV technologies. Avirmax Adeno-associated Vector Innovation Platform (AAVIP), enables us to become a “powerhouse” of rAAV therapeutics for its very infectious AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with the effective, safe, long-acting AAV-mediated biotherapeutics at the most affordable and accessible manner. Avirmax, Inc is dedicated to innovate and develop novel technologies to address current challenges in viral vector production based on its state of the art AAV bioprocess technologies in combination with Virovek’s BAC-to-AAV insect system. Avirmax has established robust rAAV vector production technologies for small and large-scale applications using Sf9-Baculovirus system.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Avirmax, Inc.?
Avirmax, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Avirmax, Inc. last raise funding?
The most recent investment in Avirmax, Inc. recorded on gritt.io was in February 2020.
When was Avirmax, Inc. founded?
Avirmax, Inc. was founded in 2019.
What industry is Avirmax, Inc. in?
Avirmax, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Avirmax, Inc. based?
Avirmax, Inc. is headquartered in Hayward, United States.